Over the past several decades, epidemiologic studies have documented declines in sperm count and quality. During the same ...

People taking GLP-1 receptor agonists appeared to be at elevated risk of rejection episodes after lung transplantation, a ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

GLP-1 receptor agonists are effective weight-loss medications, but they may also decrease muscle mass, raising concerns about ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

GLP-1 drugs like Ozempic, Mounjaro, Zepbound, originally for adults, are now prescribed for adolescents with obesity, showing ...

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

As earlier outlined, short-term studies in animals and humans have shown GLP-1 to have some direct vasorelaxation action, cardioprotective effects in models of ischemia-reperfusion injury ...

About The Study: This economic evaluation estimates that expanded Medicare coverage for glucagon-like peptide-1 receptor agonists (GLP-1RAs) would increase access and reduce obesity-related ...